{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:31:08Z","timestamp":1789691468682,"version":"4.0.1"},"reference-count":135,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T00:00:00Z","timestamp":1704326400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontierspartnerships.org"],"crossmark-restriction":true},"short-container-title":["Oncol Rev."],"abstract":"<jats:p>Liver is the most common site of colorectal cancer (CRC) metastases. Treatment of CRC liver metastases (CRLM) includes different strategies, prevalently based on the clinical and oncological intent. Valid approaches in liver-limited or liver-prevalent disease include surgery, percutaneous ablative procedures (radiofrequency ablation, microwave ablation), intra-arterial perfusional techniques (chemo-embolization, radio-embolization) as well as stereotactic radiotherapy. Systemic treatments, including chemotherapy, immunotherapy and other biological agents, are the only options for patients with no chance of locoregional approaches. The use of chemotherapy in other settings, such as neoadjuvant, adjuvant or conversion therapy of CRLM, is commonly accepted in the clinical practice, although data from several clinical trials have been mostly inconclusive. The optimal integration of all these strategies, when applicable and clinically indicated, should be ever considered in patients affected by CRLM based on clinical evidence and multidisciplinary experience. Here we revised in detail all the possible therapeutic approaches of CRLM focusing on the current evidences, the studies still in progress and the often contradictory data.<\/jats:p>","DOI":"10.3389\/or.2023.11799","type":"journal-article","created":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T23:11:00Z","timestamp":1704323460000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":21,"title":["Multimodal Management of Colorectal Liver Metastases: State of the Art"],"prefix":"10.3389","volume":"17","author":[{"given":"Elisabetta","family":"Filoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittoria","family":"Musci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Di Rito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Inchingolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Memeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Mannavola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,1,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"104","DOI":"10.3322\/caac.21220","article-title":"Colorectal Cancer Statistics","volume":"64","author":"Siegel","year":"2014","journal-title":"CA: A Cancer J Clinicians"},{"key":"B2","doi-asserted-by":"publisher","first-page":"101174","DOI":"10.1016\/j.tranon.2021.101174","article-title":"Global Colorectal Cancer Burden in 2020 and Projections to 2040","volume":"14","author":"Xi","year":"2021","journal-title":"Translational Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"4590","DOI":"10.3390\/cancers13184590","article-title":"Perioperative Systemic Chemotherapy for Colorectal Liver Metastasis: Recent Updates","volume":"13","author":"Lee","year":"2021","journal-title":"Cancers"},{"key":"B4","doi-asserted-by":"publisher","first-page":"719638","DOI":"10.3389\/fonc.2021.719638","article-title":"Development and Validation of a Predictive Scoring System for Colorectal Cancer Patients With Liver Metastasis: A Population-Based Study","volume":"11","author":"Cao","year":"2021","journal-title":"Front Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s10585-015-9719-0","article-title":"Nationwide Trends in Incidence, Treatment and Survival of Colorectal Cancer Patients With Synchronous Metastases","volume":"32","author":"Van Der Geest","year":"2015","journal-title":"Clin Exp Metastasis"},{"key":"B6","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s10585-012-9551-8","article-title":"The Tumour Biology of Synchronous and Metachronous Colorectal Liver Metastases: A Systematic Review","volume":"30","author":"Slesser","year":"2013","journal-title":"Clin Exp Metastasis"},{"key":"B7","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1245\/s10434-006-9215-5","article-title":"Clinicopathological Features and Prognosis in Resectable Synchronous and Metachronous Colorectal Liver Metastasis","volume":"14","author":"Tsai","year":"2007","journal-title":"Ann Surg Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1159\/000478791","article-title":"Prognostic Impact of Adjuvant Chemotherapy After Hepatic Resection for Synchronous and Early Metachronous Colorectal Liver Metastases","volume":"35","author":"Nishioka","year":"2017","journal-title":"Dig Surg"},{"key":"B9","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1186\/s12885-021-07941-2","article-title":"Prognostic Impact of Additive Chemotherapy After Curative Resection of Metachronous Colorectal Liver Metastasis: A Single-Centre Retrospective Study","volume":"21","author":"Kelm","year":"2021","journal-title":"BMC Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1097\/00000658-199909000-00004","article-title":"Clinical Score for Predicting Recurrence After Hepatic Resection for Metastatic Colorectal Cancer","volume":"230","author":"Fong","year":"1999","journal-title":"Ann Surg"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1002\/(sici)1097-0142(19960401)77:7<1254::aid-cncr5>3.0.co;2-i","article-title":"Surgical Resection of Colorectal Carcinoma Metastases to the Liver. A Prognostic Scoring System to Improve Case Selection, Based on 1568 Patients","volume":"77","author":"Nordlinger","year":"1996","journal-title":"Cancer"},{"key":"B12","doi-asserted-by":"publisher","first-page":"6305","DOI":"10.3748\/wjg.v12.i39.6305","article-title":"Proposal of Criteria to Select Candidates With Colorectal Liver Metastases for Hepatic Resection: Comparison of Our Scoring System to the Positive Number of Risk Factors","volume":"12","author":"Nagashima","year":"2006","journal-title":"World J Gastroenterol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/j.1478-3231.2008.01845.x","article-title":"Prognostic Factors and Evaluation of a Clinical Score for Predicting Survival After Resection of Colorectal Liver Metastases","volume":"29","author":"Konopke","year":"2009","journal-title":"Liver Int"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e1031","DOI":"10.1634\/theoncologist.2019-0797","article-title":"Comprehensive Evaluation of Relapse Risk (CERR) Score for Colorectal Liver Metastases: Development and Validation","volume":"25","author":"Chen","year":"2020","journal-title":"The Oncologist"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e0217411","DOI":"10.1371\/journal.pone.0217411","article-title":"Primary Tumour Location Affects Survival After Resection of Colorectal Liver Metastases: A Two-Institutional Cohort Study With International Validation, Systematic Meta-Analysis and a Clinical Risk Score","volume":"14","author":"Gasser","year":"2019","journal-title":"PLoS ONE"},{"key":"B16","doi-asserted-by":"publisher","first-page":"962","DOI":"10.3390\/biomedicines9080962","article-title":"Primary Tumor Sidedness, RAS and BRAF Mutations and MSI Status as Prognostic Factors in Patients With Colorectal Liver Metastases Treated With Surgery and Thermal Ablation: Results From the Amsterdam Colorectal Liver Met Registry (AmCORE)","volume":"9","author":"Dijkstra","year":"2021","journal-title":"Biomedicines"},{"key":"B17","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.ejso.2018.02.247","article-title":"SMAD4 Gene Mutation Predicts Poor Prognosis in Patients Undergoing Resection for Colorectal Liver Metastases","volume":"44","author":"Mizuno","year":"2018","journal-title":"Eur J Surg Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"5843","DOI":"10.1158\/1078-0432.ccr-19-0863","article-title":"Mutation Status of RAS, TP53, and SMAD4 Is superior to Mutation Status of Ras Alone for Predicting Prognosis After Resection of Colorectal Liver Metastases","volume":"25","author":"Kawaguchi","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B19","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/s1470-2045(21)00064-4","article-title":"Health-related Quality of Life in Patients With Microsatellite Instability-High or Mismatch Repair Deficient Metastatic Colorectal Cancer Treated With First-Line Pembrolizumab Versus Chemotherapy (KEYNOTE-177): An Open-Label, Randomised, Phase 3 Trial","volume":"22","author":"Andre","year":"2021","journal-title":"Lancet Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1200\/jco.21.01015","article-title":"First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High\/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study","volume":"40","author":"Lenz","year":"2022","journal-title":"J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1200\/jco.1995.13.1.8","article-title":"Oligometastases","volume":"13","author":"Hellman","year":"1995","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/nrclinonc.2014.96","article-title":"The Oligometastatic State - Separating Truth From Wishful Thinking","volume":"11","author":"Palma","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1067\/j.cpsurg.2018.08.004","article-title":"Cytoreduction for Colorectal Metastases: Liver, Lung, Peritoneum, Lymph Nodes, Bone, Brain. When Does It Palliate, Prolong Survival, and Potentially Cure?","volume":"55","author":"Stewart","year":"2018","journal-title":"Curr Probl Surg"},{"key":"B24","doi-asserted-by":"publisher","first-page":"7014","DOI":"10.3748\/wjg.v21.i22.7014","article-title":"Treatment Strategies for Colorectal Carcinoma With Synchronous Liver Metastases: Which Way to Go?","volume":"21","author":"Ihn\u00e1t","year":"2015","journal-title":"World J Gastroenterol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1093\/annonc\/mdh912","article-title":"Regional Treatment of Metastasis: Surgery of Colorectal Liver Metastases","volume":"15","author":"Adam","year":"2004","journal-title":"Ann Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1002\/bjs5.50174","article-title":"Multicentre Study of Perioperative Versus Adjuvant Chemotherapy for Resectable Colorectal Liver Metastases","volume":"3","author":"Allard","year":"2019","journal-title":"BJS Open"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1245\/s10434-006-9023-y","article-title":"Selection of Patients for Resection of Hepatic Colorectal Metastases: Expert Consensus Statement","volume":"13","author":"Charnsangavej","year":"2006","journal-title":"Ann Surg Oncol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"832405","DOI":"10.3389\/fonc.2022.832405","article-title":"Liver-Directed Treatment Options Following Liver Tumor Recurrence: A Review of the Literature","volume":"12","author":"Aquina","year":"2022","journal-title":"Front Oncol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.surg.2018.09.005","article-title":"The Impact of R1 Resection for Colorectal Liver Metastases on Local Recurrence and Overall Survival in the Era of Modern Chemotherapy: An Analysis of 1,428 Resection Areas","author":"Ardito","year":"2018","journal-title":"Surgery"},{"key":"B30","doi-asserted-by":"publisher","first-page":"0748","DOI":"10.1016\/j.ejso.2019.12.004","article-title":"Does KRAS Mutation Status Impact the Risk of Local Recurrence After R1 Vascular Resection for Colorectal Liver Metastasis? An Observational Cohort Study","author":"Procopio","year":"2019","journal-title":"Eur J Surg Oncol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1097\/00000658-200206000-00002","article-title":"Trends in Long-Term Survival Following Liver Resection for Hepatic Colorectal Metastases","volume":"235","author":"Choti","year":"2002","journal-title":"Ann Surg"},{"key":"B32","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1097\/01.sla.0000160703.75808.7d","article-title":"Effect of Surgical Margin Status on Survival and Site of Recurrence After Hepatic Resection for Colorectal Metastases","volume":"241","author":"Pawlik","year":"2005","journal-title":"Ann Surg"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2472","DOI":"10.1245\/s10434-008-0023-y","article-title":"Appraisal of 1 Cm Hepatectomy Margins for Intrahepatic Micrometastases in Patients With Colorectal Carcinoma Liver Metastasis","volume":"15","author":"Wakai","year":"2008","journal-title":"Ann Surg Oncol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1007\/s00595-021-02254-0","article-title":"Resection Strategy for Colorectal Liver Metastasis Focusing on Intrahepatic Vessels and Resection Margins","volume":"51","author":"Iwaki","year":"2021","journal-title":"Surg Today"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1245\/s10434-015-5009-y","article-title":"Is Tumor Detachment From Vascular Structures Equivalent to R0 Resection in Surgery for Colorectal Liver Metastases? An Observational Cohort","volume":"23","author":"Vigan\u00f2","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1158\/0008-5472.can-06-4158","article-title":"Oncogenic Activation of the RAS\/RAF Signaling Pathway Impairs the Response of Metastatic Colorectal Cancers to Anti\u2013 Epidermal Growth Factor Receptor Antibody Therapies","volume":"67","author":"Benvenuti","year":"2007","journal-title":"Cancer Res"},{"key":"B37","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1245\/s10434-016-5609-1","article-title":"KRAS Mutation Status Dictates Optimal Surgical Margin Width in Patients Undergoing Resection of Colorectal Liver Metastases","volume":"24","author":"Margonis","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000002367","article-title":"Anatomical Resections Improve Disease-Free Survival in Patients With KRAS-Mutated Colorectal Liver Metastases","author":"Margonis","year":"2017","journal-title":"Ann Surg"},{"key":"B39","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/hpb.12316","article-title":"Tumour Biology of Colorectal Liver Metastasis Is a More Important Factor in Survival Than Surgical Margin Clearance in the Era of Modern Chemotherapy Regimens","volume":"17","author":"Truant","year":"2015","journal-title":"Int Hepato-Pancreatic-Biliary Assoc"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1007\/s11605-016-3198-8","article-title":"Tumor Biology Rather Than Surgical Technique Dictates Prognosis in Colorectal Cancer Liver Metastases","volume":"20","author":"Margonis","year":"2016","journal-title":"J Gastrointest Surg"},{"key":"B41","doi-asserted-by":"publisher","first-page":"147","DOI":"10.20524\/aog.2018.0338","article-title":"The Role of Interventional Oncology in the Treatment of Colorectal Cancer Liver Metastases","volume":"32","author":"Tsitskari","year":"2019","journal-title":"Ann Gastroenterol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1186\/s12885-018-4716-8","article-title":"Colorectal Liver Metastases: Surgery Versus Thermal Ablation (COLLISION) \u2013 A Phase III Single-Blind Prospective Randomized Controlled Trial","volume":"18","author":"PuijK","year":"2018","journal-title":"BMC Cancer"},{"key":"B43","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1148\/radiographics.21.suppl_1.g01oc11s17","article-title":"Essential Techniques for Successful Radio-Frequency Thermal Ablation of Malignant Hepatic Tumors","volume":"21","author":"Rhim","year":"2001","journal-title":"RadioGraphics"},{"key":"B44","doi-asserted-by":"publisher","first-page":"508","DOI":"10.4261\/1305-3825.dir.5168-11.1","article-title":"Radiofrequency Ablation: Technique and Clinical Applications","volume":"18","author":"Tatli","year":"2012","journal-title":"Diagn Interv Radiol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1007\/s00270-012-0377-1","article-title":"Margin Size Is an Independent Predictor of Local Tumor Progression After Ablation of Colon Cancer Liver Metastases","volume":"36","author":"Wang","year":"2013","journal-title":"Cardiovasc Intervent Radiol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1093\/annonc\/mds053","article-title":"Radiofrequency Ablation Combined With Systemic Treatment Versus Systemic Treatment Alone in Patients With Non-Resectable Colorectal Liver Metastases: A Randomized EORTC Intergroup Phase II Study (EORTC 40004)","volume":"23","author":"Ruers","year":"2012","journal-title":"Ann Oncol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"S192","DOI":"10.1016\/j.jvir.2010.04.007","article-title":"Microwave Tumor Ablation: Mechanism of Action, Clinical Results and Devices","volume":"21","author":"Lubner","year":"2010","journal-title":"J Vasc Interv Radiol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.jvir.2017.08.021","article-title":"Percutaneous Microwave Versus Radiofrequency Ablation of Colorectal Liver Metastases: Ablation With Clear Margins (A0) Provides the Best Local Tumor Control","volume":"29","author":"Shady","year":"2018","journal-title":"J Vasc Interv Radiol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/s41598-021-03802-x","article-title":"Microwave Versus Radiofrequency Ablation for the Treatment of Liver Malignancies: A Randomized Controlled Phase 2 Trial","volume":"12","author":"Radosevic","year":"2022","journal-title":"Scientific Rep"},{"key":"B50","doi-asserted-by":"publisher","first-page":"W424","DOI":"10.2214\/ajr.08.1836","article-title":"Percutaneous Radiofrequency Ablation of Hepatocellular Carcinoma: Assessment of Safety in Patients With Ascites","volume":"193","author":"Cha","year":"2009","journal-title":"Am J Roentgenology"},{"key":"B51","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1080\/02656736.2018.1539776","article-title":"Radiofrequency Ablation of Liver Cancers Adjacent to the Gallbladder Withoutgallbladder Isolation Under Contrast-Enhanced Ultrasound Monitoring: Apreliminary Study","volume":"36","author":"Long","year":"2019","journal-title":"Int J Hyperthermia"},{"key":"B52","first-page":"E169","article-title":"Review of the Safety of Bipolar Radiofrequency Ablation in Patients With Chronic Pain With Implantable Cardiac Rhythm Management Devices","volume":"24","author":"Hanna","year":"2021","journal-title":"Pain Physician"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.cd009498.pub4","article-title":"Transarterial (Chemo)embolisation Versus No Intervention or Placebo for Liver Metastases","volume":"2020","author":"Swierz","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"B54","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.3390\/jcm9072302","article-title":"The Role of Interventional Radiology for the Treatment of Hepatic Metastases From Neuroendocrine Tumor: An Updated Review","volume":"9","author":"Barat","year":"2020","journal-title":"J Clin Med"},{"key":"B55","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1055\/s-0033-1333649","article-title":"Intra-Arterial Therapies for Metastatic Colorectal Cancer","volume":"30","author":"Wang","year":"2013","journal-title":"Semin Intervent Radiol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s00270-020-02646-8","article-title":"The CIREL Cohort: A Prospective Controlled Registry Studying the Real-Life Use of Irinotecan-Loaded Chemoembolisation in Colorectal Cancer Liver Metastases: Interim Analysis","volume":"44","author":"Pereira","year":"2021","journal-title":"Cardiovasc Intervent Radiol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.21037\/jgo-21-96","article-title":"Narrative Review of the Role of Yttrium-90 Selective Internal Radiation Therapy in the Surgical Management of Colorectal Liver Metastases","volume":"12","author":"Moslim","year":"2021","journal-title":"J Gastrointest Oncol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"3687","DOI":"10.1200\/jco.2010.28.5643","article-title":"Phase III Trial Comparing Protracted Intravenous Fluorouracil Infusion Alone or With Yttrium-90 Resin Microspheres Radioembolization for Liver-Limited Metastatic Colorectal Cancer Refractory to Standard Chemotherapy","volume":"28","author":"Hendlisz","year":"2010","journal-title":"J Clin Oncol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/s1470-2045(17)30457-6","article-title":"First-Line Selective Internal Radiotherapy Plus Chemotherapy Versus Chemotherapy Alone in Patients With Liver Metastases From Colorectal Cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): A Combined Analysis of Three Multicentre, Randomised, Phase 3 Trials","volume":"18","author":"Wasan","year":"2017","journal-title":"Lancet Oncol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"e617","DOI":"10.1016\/j.clcc.2018.06.001","article-title":"Effect of Primary Tumor Side on Survival Outcomes in Untreated Patients With Metastatic Colorectal Cancer When Selective Internal Radiation Therapy Is Added to Chemotherapy: Combined Analysis of Two Randomized Controlled Studies","volume":"17","author":"Gibbs","year":"2018","journal-title":"Clin Colorectal Cancer"},{"key":"B61","doi-asserted-by":"publisher","first-page":"3897","DOI":"10.1200\/jco.21.01839","article-title":"Radioembolization With Chemotherapy for Colorectal Liver Metastases: A Randomized, Open-Label, International, Multicenter, Phase III Trial","volume":"39","author":"Mulcahy","year":"2021","journal-title":"J Clin Oncol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"665","DOI":"10.2967\/jnumed.115.166082","article-title":"90Y Radioembolization of Colorectal Hepatic Metastases Using Glass Microspheres: Safety and Survival Outcomes From a 531-Patient Multicenter Study","volume":"57","author":"Hickey","year":"2016","journal-title":"J Nucl Med"},{"key":"B63","doi-asserted-by":"publisher","first-page":"087","DOI":"10.1055\/s-0037-1601854","article-title":"Decision Making in Interventional Oncology: Intra-Arterial Therapies for Metastatic Colorectal Cancer\u2014Y90 and Chemoembolization","volume":"34","author":"Fairchild","year":"2017","journal-title":"Semin Interv Radiol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.ijrobp.2017.04.010","article-title":"Long-Term Outcomes of Phase 1 and 2 Studies of SBRT for Hepatic Colorectal Metastases","volume":"99","author":"McPartlin","year":"2017","journal-title":"Int J Radiat Oncology*Biology*Physics"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1016\/j.ijrobp.2020.11.045","article-title":"The Dutch-Belgian Registry of Stereotactic Body Radiation Therapy for Liver Metastases: Clinical Outcomes of 515 Patients and 668 Metastases","volume":"109","author":"Mendez","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B66","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s00432-014-1833-x","article-title":"Final Results of a Phase II Trial for Stereotactic Body Radiation Therapy for Patients With Inoperable Liver Metastases From Colorectal Cancer","volume":"141","author":"Scorsetti","year":"2015","journal-title":"J Cancer Resclin Oncol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.ijrobp.2017.12.288","article-title":"Local Control After Stereotactic Body Radiation Therapy for Liver Tumors","volume":"110","author":"Ohri","year":"2021","journal-title":"Int J Radiat Oncology*Biology*Physics"},{"key":"B68","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1080\/02656736.2021.1923836","article-title":"Stereotactic Body Radiation Therapy for Colorectal Liver Metastases","volume":"39","author":"Mohamad","year":"2022","journal-title":"Int J Hyperthermia"},{"key":"B69","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.rpor.2019.12.006","article-title":"Feasibility of 4D CT Simulation With Synchronized Intravenous Contrast Injection in Hepatocellular Carcinoma","volume":"25","author":"Gupta","year":"2020","journal-title":"Rep Pract Oncol Radiother"},{"key":"B70","doi-asserted-by":"publisher","first-page":"S517","DOI":"10.21037\/jtd.2016.03.14","article-title":"Stereotactic Body Radiotherapy: Current Strategies and Future Development","volume":"8","author":"Tsang","year":"2016","journal-title":"J Thorac Dis"},{"key":"B71","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13014-015-0369-9","article-title":"Stereotactic Radiation Therapy for Liver Metastases: Factors Affecting Local Control and Survival","volume":"10","author":"Andratschke","year":"2015","journal-title":"Radiat Oncol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1200\/jco.2008.19.6329","article-title":"Multi-Institutional Phase I\/II Trial of Stereotactic Body Radiation Therapy for Liver Metastases","volume":"27","author":"Rusthoven","year":"2009","journal-title":"J Clin Oncol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1200\/jco.2014.55.4675","article-title":"Emergence of Stereotactic Body Radiation Therapy and Its Impact on Current and Future Clinical Practice","volume":"32","author":"Timmerman","year":"2014","journal-title":"J Clin Oncol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1200\/jco.20.00818","article-title":"Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial","volume":"38","author":"Palma","year":"2020","journal-title":"J Clin Oncol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3978\/j.issn.2078-6891.2014.039","article-title":"Stereotactic Body Radiation Therapy for Liver Metastases","volume":"5","author":"Scorsetti","year":"2014","journal-title":"J Gastrointest Oncol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"591","DOI":"10.21873\/anticanres.12263","article-title":"Stereotactic Body Radiation Therapy for Liver Tumors: Current Status and Perspectives","volume":"38","author":"Doi","year":"2018","journal-title":"Anticancer Res"},{"key":"B77","doi-asserted-by":"publisher","first-page":"S94","DOI":"10.1016\/j.ijrobp.2009.06.092","article-title":"Radiation-Associated Liver Injury","volume":"76","author":"Pan","year":"2010","journal-title":"Int J Radiat Oncology*Biology*Physics"},{"key":"B78","doi-asserted-by":"publisher","first-page":"112","DOI":"10.21037\/jgo.2018.08.17","article-title":"A Phase I Trial of Proton Stereotactic Body Radiation Therapy for Liver Metastases","volume":"10","author":"Kang","year":"2018","journal-title":"J Gastrointest Oncol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"616027","DOI":"10.3389\/fonc.2021.616027","article-title":"MR-Guided Radiotherapy for Liver Malignancies","volume":"11","author":"Boldrini","year":"2021","journal-title":"Front Oncol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"06577","DOI":"10.1016\/j.radonc.2021.06.005","article-title":"Ablative Radiotherapy for Liver Tumors Using Stereotactic MRI Guidance: A Prospective Phase I Trial","author":"Van Dams","year":"2021","journal-title":"Radiother Oncol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ijrobp.2019.02.046","article-title":"Immunomodulatory Effects of Stereotactic Body Radiation Therapy: Preclinical Insights and Clinical Opportunities","volume":"110","author":"Marciscano","year":"2021","journal-title":"Int J Radiat Oncology*Biology*Physics"},{"key":"B82","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1097\/ppo.0000000000000181","article-title":"Preclinical Rationale and Clinical Considerations for Radiotherapy Plus Immunotherapy: Going Beyond Local Control","volume":"22","author":"Schoenhals","year":"2016","journal-title":"Cancer J"},{"key":"B83","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.hpb.2016.03.001","article-title":"Systematic Review of Systemic Adjuvant, Neoadjuvant and Perioperative Chemotherapy for Resectable Colorectal-Liver Metastases","volume":"18","author":"Khoo","year":"2016","journal-title":"HPB"},{"key":"B84","doi-asserted-by":"publisher","first-page":"3535","DOI":"10.3390\/cancers12123535","article-title":"Perioperative Chemotherapy for Liver Metastasis of Colorectal Cancer","volume":"12","author":"Chan","year":"2020","journal-title":"Cancers"},{"key":"B85","doi-asserted-by":"publisher","first-page":"4263","DOI":"10.1245\/s10434-020-08777-z","article-title":"The Landmark Series: Randomized Control Trials Examining Perioperative Chemotherapy and Postoperative Adjuvant Chemotherapy for Resectable Colorectal Liver Metastasis","volume":"27","author":"Kawaguchi","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60455-9","article-title":"Perioperative Chemotherapy With FOLFOX4 and Surgery Versus Surgery Alone for Resectable Liver Metastases From Colorectal Cancer (EORTC Intergroup Trial 40983): A Randomised Controlled Trial","volume":"371","author":"Nordlinger","year":"2008","journal-title":"The Lancet"},{"key":"B87","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/s1470-2045(13)70447-9","article-title":"Perioperative FOLFOX4 Chemotherapy and Surgery Versus Surgery Alone for Resectable Liver Metastases From Colorectal Cancer (EORTC 40983): Long-Term Results of a Randomised, Controlled, Phase 3 Trial","volume":"14","author":"Nordlinger","year":"2013","journal-title":"Lancet Oncol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/s1470-2045(19)30798-3","article-title":"Systemic Chemotherapy With or Without Cetuximab in Patients With Resectable Colorectal Liver Metastasis (New EPOC): Long-Term Results of a Multicentre, Randomised, Controlled, Phase 3 Trial","volume":"21","author":"Bridgewater","year":"2020","journal-title":"Lancet Oncol"},{"key":"B89","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1200\/jco.2010.33.5091","article-title":"Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin as First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status","volume":"29","author":"Van Cutsem","year":"2011","journal-title":"J Clin Oncol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/s1470-2045(14)70105-6","article-title":"Systemic Chemotherapy With or Without Cetuximab in Patients With Resectable Colorectal Liver Metastasis: The New EPOC Randomised Controlled Trial","volume":"15","author":"Primrose","year":"2014","journal-title":"Lancet Oncol"},{"key":"B91","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/j.1477-2574.2009.00119.x","article-title":"Perioperative Chemotherapy With Bevacizumab and Liver Resection for Colorectal Cancer Liver Metastasis","volume":"12","author":"Chaudhury","year":"2010","journal-title":"HPB"},{"key":"B92","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.clcc.2012.07.002","article-title":"Perioperative Chemotherapy With or Without Bevacizumab in Patients With Metastatic Colorectal Cancer Undergoing Liver Resection","volume":"12","author":"Constantinidou","year":"2013","journal-title":"Clin Colorectal Cancer"},{"key":"B93","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.21037\/jgo.2019.06.03","article-title":"Making Sense of Adjuvant Chemotherapy in Colorectal Cancer","volume":"10","author":"Chan","year":"2019","journal-title":"J Gastrointest Oncol"},{"key":"B94","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1245\/s10434-010-1409-1","article-title":"Effect on Outcome of Recurrence Patterns After Hepatectomy for Colorectal Metastases","volume":"18","author":"D\u2019Angelica","year":"2011","journal-title":"Ann Surg Oncol"},{"key":"B95","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","article-title":"ESMO Consensus Guidelines for the Management of Patients With Metastatic Colorectal Cancer","volume":"27","author":"Van Cutsem","year":"2016","journal-title":"Ann Oncol"},{"key":"B96","doi-asserted-by":"publisher","first-page":"e000343","DOI":"10.1136\/esmoopen-2018-000343","article-title":"Postoperative Chemotherapy With Single-Agent Fluoropyrimidines After Resection of Colorectal Cancer Liver Metastases: A Meta-Analysis of Randomised Trials","volume":"3","author":"Mauri","year":"2018","journal-title":"ESMO Open"},{"key":"B97","doi-asserted-by":"publisher","first-page":"4976","DOI":"10.1200\/jco.2006.06.8353","article-title":"Multicenter Randomized Trial of Adjuvant Fluorouracil and Folinic Acid Compared With Surgery Alone After Resection of Colorectal Liver Metastases: FFCD ACHBTH AURC 9002 Trial","volume":"24","author":"Portier","year":"2006","journal-title":"J Clin Oncol"},{"key":"B98","doi-asserted-by":"publisher","first-page":"4906","DOI":"10.1200\/jco.2008.17.3781","article-title":"Adjuvant Chemotherapy After Potentially Curative Resection of Metastases From Colorectal Cancer: A Pooled Analysis of Two Randomized Trials","volume":"26","author":"Mitry","year":"2008","journal-title":"J Clin Oncol"},{"key":"B99","doi-asserted-by":"publisher","first-page":"e0162400","DOI":"10.1371\/journal.pone.0162400","article-title":"Adjuvant Oral Uracil-Tegafur With Leucovorin for Colorectal Cancer Liver Metastases: A Randomized Controlled Trial","volume":"11","author":"Hasegawa","year":"2016","journal-title":"PLOS One"},{"key":"B100","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1200\/jco.2020.38.4_suppl.7","article-title":"A Randomized Phase III Trial Comparing Primary Tumor Resection Plus Chemotherapy With Chemotherapy Alone in Incurable Stage IV Colorectal Cancer: JCOG1007 Study (iPACS)","volume":"38","author":"Kanemitsu","year":"2020","journal-title":"J Clin Oncol"},{"key":"B101","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1093\/bjs\/znaa145","article-title":"Centralized Repeated Resectability Assessment of Patients With Colorectal Liver Metastases During First-Line Treatment: Prospective Study","volume":"108","author":"Isoniemi","year":"2021","journal-title":"Br J Surg"},{"key":"B102","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1097\/01.sla.0000141198.92114.f6","article-title":"Rescue Surgery for Unresectable Colorectal Liver Metastases Downstaged by Chemotherapy A Model to Predict Long-Term Survival","volume":"240","author":"Adam","year":"2004","journal-title":"Ann Surg"},{"key":"B103","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1097\/01.sla.0000098112.04758.4e","article-title":"Liver Resection for Colorectal Metastases the Third Hepatectomy","volume":"238","author":"Adam","year":"2003","journal-title":"Ann Surg"},{"key":"B104","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1097\/sla.0000000000002064","article-title":"The Tumor Burden Score: A New \u2018Metro-Ticket\u2019 Prognostic Tool for Colorectal Liver Metastases Based on Tumor Size and Number of Tumors","volume":"267","author":"Sasaki","year":"2018","journal-title":"Ann Surg"},{"key":"B105","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1002\/jso.24678","article-title":"The Prognostic Utility of the \u2018Tumor Burden Score\u2019 Based on Preoperative Radiographic Features of Colorectal Liver Metastases","volume":"116","author":"Sasaki","year":"2017","journal-title":"J Surg Oncol"},{"key":"B106","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/17562848211066206","article-title":"Application of Tumor Burden Score for Predicting Conversion Outcome in Patients With Initially Unresectable Colorectal Liver Metastases After First-Line Systemic Therapy","volume":"14","author":"Peng","year":"2021","journal-title":"Ther Adv Gastroenterol"},{"key":"B107","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/annonc\/mdv112","article-title":"Early Tumor Shrinkage and Depth of Response Predict Long-Term Outcome in Metastatic Clorectal Cancer Patients Treated With First-Line Chemotherapy Plus Bevacizumab: Results From Phase III TRIBE Trial by the Gruppo Oncologico del Nord Ovest","author":"Cremolini","year":"2015","journal-title":"Ann Oncol"},{"key":"B108","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1093\/annonc\/mdu580","article-title":"Bevacizumab Plus mFOLFOX-6 or FOLFOXIRI in Patients With Initially Unresectable Liver Metastases From Colorectal Cancer: The OLIVIA Multinational Randomised Phase II Trial","volume":"26","author":"Gruenberger","year":"2015","journal-title":"Ann Oncol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.0278","article-title":"FOLFOXIRI Plus Bevacizumab as Conversion Therapy for Patients With Initially Unresectable Metastatic Colorectal Cancer","volume":"3","author":"Tomasello","year":"2017","journal-title":"Jama Oncol"},{"key":"B110","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1007\/s10147-018-01393-8","article-title":"mFOLFOX6 Plus Bevacizumab to Treat Liver-Only Metastases of Colorectal Cancer that Are Unsuitable for Upfront Resection (TRICC0808): A Multicenter Phase II Trial Comprising the Final Analysis for Survival","volume":"24","author":"Yasuno","year":"2019","journal-title":"Int J Clin Oncol"},{"key":"B111","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1001\/jama.2023.4428","article-title":"Panitumumab vs Bevacizumab Added to Standard First-Line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial","volume":"329","author":"Watanabe","year":"2023","journal-title":"JAMA"},{"key":"B112","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1515\/iss-2018-0012","article-title":"First-Line Molecular Therapies in the Treatment of Metastatic Colorectal Cancer \u2013 A Literature-Based Review of Phases II and III Trials","volume":"3","author":"Vogel","year":"2018","journal-title":"Innov Surg Sci"},{"key":"B113","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1093\/annonc\/mdx175","article-title":"Prognostic and Predictive Value of Primary Tumour Side in Patients With RAS Wild-Type Metastatic Colorectal Cancer Treated With Chemotherapy and EGFR Directed Antibodies in Six Randomized Trials","volume":"28","author":"Arnold","year":"2017","journal-title":"Ann Oncol"},{"key":"B114","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA1","volume-title":"Panitumumab (PAN) Plus mFOLFOX6 Versus Bevacizumab (BEV) Plus mFOLFOX6 as First-Line Treatment in Patients With RAS Wild-Type (WT) Metastatic Colorectal Cancer (mCRC): Results From the Phase 3 PARADIGM Trial","author":"Yoshino","year":"2022"},{"key":"B115","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/nejmoa2017699","article-title":"Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer","volume":"383","author":"Andr\u00e9","year":"2020","journal-title":"New Engl J Med"},{"key":"B116","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/s41591-020-0805-8","article-title":"Neoadjuvant Immunotherapy Leads to Pathological Responses in MMR-Proficient and MMR-Deficient Early-Stage Colon Cancers","volume":"26","author":"Chalabi","year":"2020","journal-title":"Nat Med"},{"key":"B117","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1056\/nejmoa2201445","article-title":"PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer","volume":"386","author":"Cercek","year":"2022","journal-title":"New Engl J Med"},{"key":"B118","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1093\/jnci\/djaa052","article-title":"Pathological Tumor Response Following Immune Checkpoint Blockade for Deficient Mismatch Repair Advanced Colorectal Cancer","volume":"113","author":"Ludford","year":"2021","journal-title":"JNCI: J Natl Cancer Inst"},{"key":"B119","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1093\/bjs\/znab342","article-title":"Neoadjuvant Immunotherapy in Primary and Metastatic Colorectal Cancer","volume":"108","author":"Kanani","year":"2021","journal-title":"Br J Surg"},{"key":"B120","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00104-013-2563-3","article-title":"Computed Tomographic Morphological Evaluation of Neoadjuvant Chemotherapy. Effectiveness of the Therapy for Colorectal Liver Metastases","volume":"85","author":"Folprecht","year":"2014","journal-title":"Chirurg"},{"key":"B121","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.jceh.2014.10.002","article-title":"Sinusoidal Obstruction Syndrome (Hepatic Veno-Occlusive Disease)","volume":"4","author":"Fan","year":"2014","journal-title":"J Clin Exp Hepatol"},{"key":"B122","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1200\/jco.2005.05.3074","article-title":"Chemotherapy Regimen Predicts Steatohepatitis and an Increase in 90-Day Mortality After Surgery for Hepatic Colorectal Metastases","volume":"24","author":"Vauthey","year":"2006","journal-title":"J Clin Oncol"},{"key":"B123","doi-asserted-by":"publisher","first-page":"e193","DOI":"10.1016\/j.jviscsurg.2010.06.004","article-title":"Chemotherapy\u2019s Hepatotoxicity: What Is the Impact on Surgery?","volume":"147","author":"Pessaux","year":"2010","journal-title":"J Visc Surg"},{"key":"B124","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.ejso.2008.12.013","article-title":"Bevacizumab Protects Against Sinusoidal Obstruction Syndrome and Does Not Increase Response Rate in Neoadjuvant XELOX\/FOLFOX Therapy of Colorectal Cancer Liver Metastases","volume":"35","author":"Klinger","year":"2009","journal-title":"Eur J Surg Oncol (Ejso)"},{"key":"B125","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s00534-008-0016-z","article-title":"Patterns of Chemotherapy-Induced Hepatic Injury and Their Implications for Patients Undergoing Liver Resection for Colorectal Liver Metastases","volume":"16","author":"Khan","year":"2009","journal-title":"J Hepatobiliary Pancreat Surg"},{"key":"B126","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jamcollsurg.2012.08.030","article-title":"Preoperative Chemotherapy and the Risk of Hepatotoxicity and Morbidity After Liver Resection for Metastatic Colorectal Cancer: A Single Institution Experience","volume":"216","author":"Wolf","year":"2013","journal-title":"J Am Coll Surgeons"},{"key":"B127","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1097\/pas.0b013e3181dc242c","article-title":"Chemotherapy-Induced Liver Injury in Metastatic Colorectal Cancer: Semiquantitative Histologic Analysis of 334 Resected Liver Specimens Shows That Vascular Injury But Not Steatohepatitis Is Associated With Preoperative Chemotherapy","volume":"34","author":"Ryan","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"B128","doi-asserted-by":"publisher","first-page":"S18","DOI":"10.1016\/s0021-7697(10)70004-1","article-title":"Does Bevacizumab Have a Protective Effect on Hepatotoxicity Induced by Chemotherapy?","volume":"147","author":"Zalinski","year":"2010","journal-title":"J de chirurgie"},{"key":"B129","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1186\/s12957-020-02037-w","article-title":"Imaging in Disappearing Colorectal Liver Metastases and Their Accuracy: A Systematic Review","volume":"18","author":"Barimani","year":"2020","journal-title":"World J Surg Oncol"},{"key":"B130","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1126\/scitranslmed.aaf6219","article-title":"Circulating Tumor DNA Analysis Detects Minimal Residual Disease and Predicts Recurrence in Patients With Stage II colon Cancer","volume":"8","author":"Tie","year":"2016","journal-title":"Sci Transl Med"},{"key":"B131","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1093\/annonc\/mdz390","article-title":"Targeted Next-Generation Sequencing of Circulating-Tumor DNA for Tracking Minimal Residual Disease in Localized Colon Cancer","volume":"30","author":"Tarazona","year":"2019","journal-title":"Ann Oncol"},{"key":"B132","doi-asserted-by":"publisher","first-page":"3522","DOI":"10.1200\/jco.2017.35.15_suppl.3522","article-title":"Circulating Tumor DNA (ctDNA) Utilizing a High-Sensitivity Panel to Detect Minimal Residual Disease Post Liver Hepatectomy and Predict Disease Recurrence","volume":"35","author":"Overman","year":"2017","journal-title":"J Clin Oncol"},{"key":"B133","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1200\/po.20.00276","article-title":"ctDNA MRD Detection and Personalized Oncogenomic Analysis in Oligometastatic Colorectal Cancer From Plasma and Urine","volume":"5","author":"Pellini","year":"2021","journal-title":"JCO Precision Oncol"},{"key":"B134","doi-asserted-by":"publisher","first-page":"e2200244","DOI":"10.1200\/po.22.00244","article-title":"Circulating Tumor DNA as a Marker of Minimal Residual Disease After Radical Resection of Colorectal Liver Metastases","volume":"6","author":"Marmorino","year":"2022","journal-title":"JCO Precision Oncol"},{"key":"B135","doi-asserted-by":"publisher","first-page":"516","DOI":"10.3390\/cells8060516","article-title":"Circulating Tumor Cells and Circulating Tumor DNA Detection in Potentially Resectable Metastatic Colorectal Cancer: A Prospective Ancillary Study to the Unicancer Prodige-14 Trial","volume":"28","author":"Bidard","year":"2019","journal-title":"Cells"}],"container-title":["Oncology Reviews"],"original-title":[],"link":[{"URL":"https:\/\/www.frontierspartnerships.org\/articles\/10.3389\/or.2023.11799\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T08:16:34Z","timestamp":1787040994000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/journals\/oncology-reviews\/articles\/10.3389\/or.2023.11799\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,4]]},"references-count":135,"alternative-id":["10.3389\/or.2023.11799"],"URL":"https:\/\/doi.org\/10.3389\/or.2023.11799","relation":{},"ISSN":["1970-5565"],"issn-type":[{"value":"1970-5565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,4]]},"article-number":"11799"}}